• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

随机对照试验的安全性数据:应用于复发事件的模型

Safety data from randomized controlled trials: applying models for recurrent events.

作者信息

Hengelbrock Johannes, Gillhaus Johanna, Kloss Sebastian, Leverkus Friedhelm

机构信息

University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Pfizer Deutschland GmbH, Berlin, Germany.

出版信息

Pharm Stat. 2016 Jul;15(4):315-23. doi: 10.1002/pst.1757. Epub 2016 Jun 12.

DOI:10.1002/pst.1757
PMID:27291933
Abstract

Simple descriptive listings and inference statistics based on 2×2 tables are still the most common way of summarizing and reporting adverse events data from randomized controlled trials, although these methods do not account for differences in observation times between treatment groups. Using standard methods from survival analysis such as the Cox model or Kaplan-Meier estimates would overcome this problem but limit the analysis to the first safety-related event of each subject. As an alternative, we discuss two models for recurrent events data-the Andersen-Gill and Prentice-Williams-Peterson model-regarding their applicability to safety data from randomized controlled trials. We argue that these models can be used to estimate two different quantities: a direct treatment effect on the risk of an event (Prentice-Williams-Peterson) and a total treatment effect as sum of the direct effect and the treatment's indirect effect via the event history (Anderson-Gill). Using simulated data, we illustrate the difference between these treatment effects and analyze the performance of both models in different scenarios. Because both models are limited to the analysis of cause-specific hazards if competing risks are present, we suggest to incorporate estimates of the mean frequency of events in the analysis to additionally allow the comparison of treatment effects on absolute event probabilities. We demonstrate the application of both models and the mean frequency function to safety endpoints with an illustrative analysis of data from a randomized phase-III study. Copyright © 2016 John Wiley & Sons, Ltd.

摘要

基于2×2表格的简单描述性列表和推断统计仍然是总结和报告随机对照试验不良事件数据最常用的方法,尽管这些方法没有考虑治疗组之间观察时间的差异。使用生存分析的标准方法,如Cox模型或Kaplan-Meier估计,将克服这个问题,但会将分析局限于每个受试者的首次安全相关事件。作为一种替代方法,我们讨论了两种用于复发事件数据的模型——Andersen-Gill模型和Prentice-Williams-Peterson模型——并探讨它们在随机对照试验安全数据中的适用性。我们认为这些模型可用于估计两个不同的量:对事件风险的直接治疗效果(Prentice-Williams-Peterson模型)以及作为直接效果与通过事件历史的治疗间接效果之和的总治疗效果(Anderson-Gill模型)。通过模拟数据,我们说明了这些治疗效果之间的差异,并分析了两种模型在不同场景下的性能。由于如果存在竞争风险,这两种模型都局限于特定原因风险的分析,我们建议在分析中纳入事件平均频率的估计值,以便额外地比较治疗对绝对事件概率的影响。我们通过对一项随机III期研究数据的实例分析,展示了这两种模型以及平均频率函数在安全终点方面的应用。版权所有© 2016 John Wiley & Sons, Ltd.

相似文献

1
Safety data from randomized controlled trials: applying models for recurrent events.随机对照试验的安全性数据:应用于复发事件的模型
Pharm Stat. 2016 Jul;15(4):315-23. doi: 10.1002/pst.1757. Epub 2016 Jun 12.
2
Statistical issues in the analysis of adverse events in time-to-event data.事件发生时间数据中不良事件分析的统计学问题。
Pharm Stat. 2016 Jul;15(4):297-305. doi: 10.1002/pst.1739. Epub 2016 Mar 1.
3
The importance of varying the event generation process in simulation studies of statistical methods for recurrent events.在复发事件统计方法的模拟研究中改变事件生成过程的重要性。
Stat Med. 2006 Jan 15;25(1):165-79. doi: 10.1002/sim.2310.
4
A systematic comparison of recurrent event models for application to composite endpoints.系统比较应用于复合终点的复发事件模型。
BMC Med Res Methodol. 2018 Jan 4;18(1):2. doi: 10.1186/s12874-017-0462-x.
5
Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials.随机临床试验中首次事件时间和复发性事件方法的比较。
Circulation. 2018 Aug 7;138(6):570-577. doi: 10.1161/CIRCULATIONAHA.117.033065.
6
Analysing adverse events by time-to-event models: the CLEOPATRA study.通过事件发生时间模型分析不良事件:CLEOPATRA研究。
Pharm Stat. 2016 Jul;15(4):306-14. doi: 10.1002/pst.1758. Epub 2016 Jun 16.
7
Statistical methods to analyze adverse events data of randomized clinical trials.分析随机临床试验不良事件数据的统计方法。
J Biopharm Stat. 2009 Sep;19(5):889-99. doi: 10.1080/10543400903105463.
8
Is intraoperative dexmedetomidine a new option for postoperative pain treatment? A meta-analysis of randomized controlled trials.术中右美托咪定是否为术后疼痛治疗的新选择?一项随机对照试验的荟萃分析。
Pain. 2013 Jul;154(7):1140-9. doi: 10.1016/j.pain.2013.03.029. Epub 2013 Mar 27.
9
Causal inference methods to assess safety upper bounds in randomized trials with noncompliance.在存在不依从性的随机试验中评估安全性上限的因果推断方法。
Clin Trials. 2015 Jun;12(3):265-75. doi: 10.1177/1740774515572352. Epub 2015 Mar 1.
10
Analysis of recurrent events: a systematic review of randomised controlled trials of interventions to prevent falls.复发性事件分析:预防跌倒干预措施的随机对照试验系统评价
Age Ageing. 2009 Mar;38(2):151-5. doi: 10.1093/ageing/afn279. Epub 2008 Dec 23.

引用本文的文献

1
A new method for dealing with collider bias in the PWP model for recurrent events in randomized controlled trials.一种在随机对照试验中处理复发事件的PWP模型中碰撞器偏差的新方法。
BMC Med Res Methodol. 2025 May 26;25(1):142. doi: 10.1186/s12874-025-02596-0.
2
A nationwide cohort study on pneumonia infections among agriculture and healthcare workers in Taiwan.一项针对台湾农业和医护人员肺炎感染情况的全国性队列研究。
Epidemiol Infect. 2024 Dec 5;152:e156. doi: 10.1017/S0950268824001304.
3
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial.
使用补充性统计方法实现肿瘤学临床试验不良事件评估与报告的现代化:MOTIVATE试验案例研究
Invest New Drugs. 2024 Dec;42(6):664-674. doi: 10.1007/s10637-024-01481-9. Epub 2024 Nov 4.
4
Adverse events in single-arm clinical trials with non-fatal time-to-event efficacy endpoint: from clinical questions to methods for statistical analysis.单臂临床试验中具有非致命时间至疗效终点的不良事件:从临床问题到统计分析方法。
BMC Med Res Methodol. 2024 Jan 3;24(1):3. doi: 10.1186/s12874-023-02123-z.
5
An Overview of Regression Models for Adverse Events Analysis.不良事件分析回归模型概述。
Drug Saf. 2024 Mar;47(3):205-216. doi: 10.1007/s40264-023-01380-7. Epub 2023 Nov 25.
6
Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.早期不良事件衍生生物标志物在预测接受免疫治疗的晚期非小细胞肺癌患者临床结局中的作用
Cancers (Basel). 2023 Apr 28;15(9):2521. doi: 10.3390/cancers15092521.
7
Important Considerations for Signal Detection and Evaluation.信号检测与评估的重要考虑因素。
Ther Innov Regul Sci. 2023 Jul;57(4):865-874. doi: 10.1007/s43441-023-00518-0. Epub 2023 Apr 17.
8
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.用于血液透析患者高磷血症治疗的改良释放烟酰胺:3 期随机对照 NOPHOS 试验的 52 周疗效和安全性结果。
Nephrol Dial Transplant. 2023 Mar 31;38(4):982-991. doi: 10.1093/ndt/gfac206.
9
Comparison of statistical methods for the analysis of recurrent adverse events in the presence of non-proportional hazards and unobserved heterogeneity: a simulation study.存在非比例风险和未观察到的异质性时分析复发不良事件的统计方法比较:一项模拟研究。
BMC Med Res Methodol. 2022 Jan 20;22(1):24. doi: 10.1186/s12874-021-01475-8.
10
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19.受COVID-19影响的研究和提交文件的临床试验药物安全性评估。
Stat Biopharm Res. 2020 Sep 8;12(4):498-505. doi: 10.1080/19466315.2020.1804444.